Natural Products against Breast Cancer: History
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Oncology

Breast cancer (BC) is the second leading cause of death among women, and it has become a global health issue due to the increasing number of cases. Different treatment options, including radiotherapy, surgery, chemotherapy and anti-estrogen therapy, aromatase inhibitors, anti-angiogenesis drugs, and anthracyclines, are available for BC treatment. However, due to its high occurrence and disease progression, effective therapeutic options for metastatic BC are still lacking. Considering this scenario, there is an urgent need for an effective therapeutic strategy to meet the current challenges of BC. Natural products have been screened as anticancer agents as they are cost-effective, possess low toxicity and fewer side effects, and are considered alternative therapeutic options for BC therapy. Natural products showed anticancer activities against BC through the inhibition of angiogenesis, cell migrations, proliferations, and tumor growth; cell cycle arrest by inducing apoptosis and cell death, the downstream regulation of signaling pathways (such as Notch, NF-κB, PI3K/Akt/mTOR, MAPK/ERK, and NFAT-MDM2), and the regulation of EMT processes. Natural products also acted synergistically to overcome the drug resistance issue, thus improving their efficacy as an emerging therapeutic option for BC therapy. 

  • breast cancer
  • natural products
  • transcription factors
  • signaling pathways
  • treatment
  • therapeutic agents
  • combination therapy

1. Pathogenesis of Breast Cancer

Breast cancer (BC) is the most common cause of malignant tumors worldwide. BC can occur from any mutational defect in breast ducts [37]. Generally, BC is categorized on the basis of estrogen receptors into ER-positive and ER-negative breast cancers [38]. Based on specific biomarkers, BC is further categorized into subtypes, such as luminal A, B, and basal-like. TNBC is the basal-like and most severe form (see Figure 1) [39].
Figure 1. The initiation and progression of BC by obese breast adipose-derived factors. Factors released by obese breast adipose tissue may operate as mutagens, for example by activating intracellular reactive oxygen species (ROS), which can lead to DNA damage in normal breast epithelial cells and other inflammatory mediators. DNA damage may occur as a result of estrogen’s mitogenic actions, which can lead to replication stress and stress. Unresolved DNA damage, which is associated with mutagenesis and the onset of cancer, may result from increased DNA damage and possible estrogen-induced defective DNA repair. An obese breast adipose tissue microenvironment promotes BC proliferation, migration, and invasion by releasing inflammatory mediators, increasing leptin, decreasing adiponectin, and increasing estrogen levels. This figure is reproduced from Bhardwaj et al. [40] (Creative Commons Attribution License (CC BY 4.0)).
Many environmental and genetic factors increase the risk of BC. These factors include increased damage to DNA, unusual hereditary mutations, exposure to estrogen, and a lifestyle that can increase the development of BC. Patients with a family history already in the malignant phase can also increase the chances of developing BC [11]. Most of the patients inherit their susceptible genes viz p53, BRCA1, and BRCA2 [41]. Unusual mutation in CDH1 and overexpression of p53 can also increase the risk of developing BC [42]. RAS/MEK/ERK, PI3K/AKT, and RAS/MEK/ERK are the main pathways that help the normal cells to defend against cell death. Sometimes, mutational gene events in these pathways increase the chances of BC, as normal cells are incapable of committing cell suicide. For example, mutations in the PTEN gene activate the PI3K/AKT pathway, and cancerous cells are unable to go in commit suicide (see Figure 2) [43].
Figure 2. The representation of aberrant signaling pathways involved in BC. The green arrow represents the upregulation/activation, while the red arrow represents downregulation/inhibition. This figure is reproduced from Varghese et al. [44] (Creative Commons Attribution License (CC BY 4.0)).
During BC development, epithelial cells change from neoplastic cells into cancerous cells. Adipose tissues mainly contribute to the initiation and progression of BC [40]. The main factors include the inflammatory mediators and mutagens in the form of estrogens that stimulate the production of ROS that ultimately causes severe damage to DNA in epithelial cells of the breast. Increased damage to DNA induced by estrogen causes severe defects and might lead to dysfunctional DNA repair. These unusual changes in DNA increased the risk of mutagenesis of BC. BC progression is accelerated by excess estrogens leptin and inflammatory mediators which promote BC cell proliferation, migration, and invasion [45].
In BC, chronic inflammation is mediated by tumor-infiltrating lymphocytes, cancer-associated fibroblasts, tumor cells, and tumor-associated macrophages. Inflammatory actions are triggered by either necrotic cells, such as damage-associated molecular patterns (DAMPS), or products released by microorganisms, such as pathogen-associated molecular patterns (PAMPS), in the case of breast cancer. As a result, innate and adaptive immune cells secreted the chemokines and cytokines that mediate inflammatory responses [46]. Angiogenesis is initiated by the activation of angiogenesis regulators IL-6, TNF-α, NF-κB, VEGF, Jun/Fos, and LPO. Different pathways are linked with chronic inflammation in BC, such as Notch, NF-κB, PI3K/Akt/mTOR, MAPK/ERK, and NFAT-MDM2 signaling pathways, as well as the regulation of EMT processes [47]. NF-κB is the most critical mediator during chronic inflammation in breast cancer. In NF-κB pathway, activation of different genes such as IER3L, COX2, CXCL12, and CCND3 is a critical inflammatory mediator in patients with BC [48]. Various signaling pathways are activated during the inflammation of BC, which then leads to the activation of transcription factors, such as the signal transducer and activator of transcription signaling (STAT) and the activator protein 1 (AP-1) transcription factor [49].
Chronic inflammation in BC represented the seventh hallmark of cancer as compared to other malignancies. Various cellular events are major consequences of tumor progression, proliferation, and survival. Chronic inflammation indicates different events of BC, such as initiation and progression stages. Identifying different events would be helpful as an important strategy for controlling the BC among high-risk populations and prevention [50,51].

2. Recent Discoveries and Developments of Natural Products against BC

2.1. Novel Verminoside and Their Derivatives

Various adjuvant therapies have been used, including combinations of natural products, in order to improve their susceptibility to BC. These novel products have replaced or limited the use of conventional therapies due to increasing drug resistance. Different natural products have been reported influenced positive effects and could be used as adjuvant therapy by targeting tumors or affecting the EMT process [138]. For example, verminoside (VMS) from Pseudolysimachion rotundum interferes with the EMT process by suppressing the invasion and tumor growth; thus, it is widely used for BC treatment [101].
VMS has been used as an anticancer agent and exhibited inflammatory properties. Its anticancer activities have been evaluated in in vivo and in vitro models. Lee et al. [101] carried out an in vivo study in animal models (PyMT/FP635 mouse model) to investigate the anticancer potentials of VMS and showed maximum activity against MDA-MB-231 and MCF7 cells with an IC50 value of 10 µM. They found that VMS suppresses epithelial lining growth and the transition of mesenchymal breast cells without activating the ERK signaling pathway (see Table 1). Therefore, VMS can be used as a chemo-adjuvant for the treatment of BC.
VMS is a monoterpenoid that also has been isolated from K. pinanta. The biochemical nature of VMS is greatly reflected due to the presence of two hydroxyl groups that are responsible for anticancer and inflammatory properties. It is widely used for inhibiting the EMT process in BC [139]. BC cells under the EMT process have increased mesenchymal characteristics and decreased the formation of epithelial cells and cell linings [109]. These events promoted invasion and migration among BC cells. In the previous studies, it was shown that the excessive use of chemotherapeutic drugs promoted the EMT process. As a result, chemoresistance is one of the major issues tackled through the safe use of natural products as they can inhibit invasion, migration, and EMT in BC development [101].

2.2. Novel Phloroglucinol and Derivatives

Phloroglucinols are phenolic compounds that exhibit anticancer and anti-inflammatory activity. Phloroglucinol is the most important novel natural product, and its chemical structure reveals that it has an aromatic ring surrounded by hydroxyl groups. It is composed of two phloroglucinol units linked by a methylene bridge. Calcitrinone A is a type of natural product, novel phloroglucinol, isolated from C. citrinus. Calcitrinone A showed potential against MDA-MB-231 BC cells [140].
Calcitrinone A inhibited cell proliferation, invasion, and tumor growth, and stimulated apoptosis in MDA-MB-231 cells. Calcitrinone A is less toxic as compared to other drugs used for the treatment of BC. Calcitrinone A bound with the succinate-coenzyme Q reductase located at complex II of the mitochondrial membrane and blocks their activity. It resulted in the depletion of ATP levels. Calcitrinone A is the most promising anticancer agent used for BC therapy as it interferes with complex II of the mitochondria [141].
An in vivo and in vitro study was conducted by Gaafary et al. [29] to investigate the role of calcitrinone A in the chick chorioallantoic membrane (CAM) and MDA-MB-231 cells, respectively. They found that calcitrinone A interferes with mitochondrial function by blocking succinate coenzyme Q reductase and inhibiting complex II, which can untimely increase ROS production. These events induced apoptosis and cell death in MDA-MB-231 cells (see Table 1). Kim et al. [142] found that phloroglucinol inhibited the epithelial–mesenchymal transition in BC; they also found that phloroglucinol increases ROS production. They found that phloroglucinol also induced apoptosis and cell death in metastatic BC cells.

2.3. Role of Viridiflorol against BC

Viridiflorol is a natural organic compound, and its chemical structure contains a cyclopropazulen in its carbon skeleton, responsible for anticancer activity against BC. Viridiflorol, which was isolated from S. algeriensis. Furthermore, the Lamiaceae family, including the Senecio rowleyanus Jacob, Mentha aquatica L, and Ballota undulata, are excellent sources of viridiflorol derivatives [143,144]. Previous studies showed that oil secretions from S. rowleyanus contained viridiflorol (11%) that possesses anticancer and anti-inflammatory activities [145]. The oil secretions from Salvia leriifolia showed anticancer activity against BC (MCF-7 and MBA-MD-231) [146]. Viridiflorol is a class of sesquiterpenoid that isolated various aromatic plants, such as M. quinquenervia and A. edulis. Extracts of viridiflorol from these plants exhibited anticancer activities against different BC cell lines (MCF-7 and MDA-MB-231) [147]. Essential oil from Blepharocalyx salicifolius and Cyperus longus is an excellent source of viridiflorol [148,149].
Akiel et al. [27] performed an in vitro study in searching for anticancer activities of viridiflorol against BC MCF-7 cells. The tested viridiflorol showed maximum anticancer activity against MCF-7 with IC50 value of 0.1 µM. Memariani et al. [148] conducted in vitro study to investigate the anticancer potentials and apoptosis of viridiflorol. The tested derivatives of viridiflorol showed maximum anticancer activity against MCF7 with IC50 value of 31.60% and induced apoptosis at concentrations of 78.23%. Furtado et al. [149] also conducted in vitro study and successfully isolated viridiflorol from Blepharocalyx salicifolius that showed anticancer potentials against MDA-MB-231 at concentrations of 46.60 µg/mL. The isolated viridiflorol is also involved in suppressing the cellular metabolism and biological activities of BC cells.

2.4. Effect of Vulpinic Acid against BC

Vulpinic acid is a natural product that was isolated from lichens and exhibited anticancer potentials against BC. Lichens secreted a large variety of secondary metabolites effective for the treatment of BC. For example, vulpinic acid is secreted by lichenized fungi which demonstrates anticancer and anti-proliferative activities [150]. Vulpinic acid is a safe and easily assessable metabolite in nature. Vulpinic acid inhibits cell proliferation and invasion, inhibits tumor growth, and stimulates apoptosis in MC-231 cells. Vulpinic acid interacts with the FOXO-3 gene and suppresses their activity, leading to decreased expression of miRNAs [151].
In the previous studies, vulpinic acid has been used for breast treatment as it induces apoptosis and suppresses Bcl-2 [152]. Cansaran-Duman et al. [28] conducted an in vitro study and investigated the role of vulpinic acid on BC by regulating the expression of miRNA levels. They found that vulpinic acid induced apoptosis in MCF-7 by elevating the level of FOXO-3 and Bax, and suppressing Bcl-2 and pro-caspase-3,9, thus altering the tumor suppressor miRNAs (see Table 1). Kilic et al. [153] investigated the anticancer potentials of vulpinic acid against MCF-7, BT-474, MDA-MB-231, and SK-BR-3. They found that vulpinic acid showed anti-proliferative and significant inhibitory effects on the MCF-7. They also found that vulpinic acid induced apoptosis and cell death in MCF-7.

2.5. Action of Genistein against BC

Genistein is a naturally occurring compound and possesses anticancer, anti-proliferative, and anti-tumor activities. Fabaceae families are rich in genistein and its derivatives. It is also found in soybeans. It is used to overcome the drug resistance caused by BC and control the reoccurrence of metastatic invasion. It also suppresses the activities of DNA polymerase II [154]. It also arrested the cell cycle at the G2/M phase and induced apoptosis and cell death in MCF-7 and MDA-MB-231 cells. It also inhibited the cell proliferation and progression of BC. Genistein has been used for clinical uses for the prevention of BC because it increases survival rates [102].
Other studies investigated the role of genistein against BC and found that it downregulated CDK-1 and inhibited the expression of Bcl-2, as well as the function of DNA polymerase II. They also found that genistein also increased the expression of p21 and p51 [103,155]. Genistein also showed inhibitory effects on tyrosine kinases and inhibited the cancer progression. Xie et al. [156] investigated that genistein is an effective therapeutic agent that inhibits DNA methylation in MCF-7 and MDA-MB-231 cells by blocking DNA methyltransferase activity. Liu et al. [102] studied that genistein showed inhibitory potentials in the deactivation of IGF-1R and p-Akt. They also found that it decreases the level of Bcl-2 by promoting apoptosis.

This entry is adapted from the peer-reviewed paper 10.3390/molecules27113412

This entry is offline, you can click here to edit this entry!
Video Production Service